Welcome to our dedicated page for Axsome Therapeutics news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeutics stock.
Axsome Therapeutics, Inc. reports news on its biopharmaceutical business focused on central nervous system disorders, including marketed medicines and late-stage neuroscience programs. Company updates commonly cover FDA actions, product revenue for AUVELITY, SUNOSI and SYMBRAVO, business results, investor presentations, and development activity in neurological and psychiatric conditions.
Recurring topics include AUVELITY for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease, SUNOSI for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, migraine treatment commercialization, and pipeline work involving solriamfetol, AXS-12 and PDE10A inhibitor programs.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will be represented by Chief Executive Officer, Dr. Herriot Tabuteau, at two upcoming investor conferences. The company focuses on developing novel therapies for central nervous system disorders. The presentations will take place at the RBC Capital Markets 2024 Global Healthcare Conference on May 14 and the Bank of America 2024 Healthcare Conference on May 16. Investors can watch the events live on the company's website.
Axsome Therapeutics reported strong financial results for the first quarter of 2024, with total net product revenue of $75.0 million, representing significant year-over-year growth. The company announced positive Phase 3 trial results for AXS-12 in narcolepsy, with other key pipeline programs progressing well. However, the increase in research and development expenses, higher selling, general, and administrative expenses, and a net loss of $68.4 million for the quarter are some challenges highlighted in the financial report.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.